Fibroblast growth factor 23, parathyroid hormone, and 1α,25- dihydroxyvitamin D in surgically treated primary hyperparathyroidism

Mayo Clinic Proceedings

Volumn 79, Issue 12, 2004, Pages 1508-1513

  Tebben, Peter J ^a   Singh, Ravinder J ^a   Clarke, Bart L ^a   Kumar, Rajiv ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION;

EID: 9644290893     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.12.1508     Document Type: Article

References (46)

1. Albright F. A page out of the history of hyperparathyroidism. J Clin Endocrinol Metab. 1948;8:637-657.
2. Arnaud CD, Tsao HS, Littledike T. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest. 1971;50:21-34.
3. Duh QY, Arnaud CD, Levin KE, Clark OH. Parathyroid hormone: before and after parathyroidectomy. Surgery. 1986;100:1021-1031.
4. Manning RM, Hendy GN, Papapoulos SE, O'Riordan JL. Development of homologous immunological assays for human parathyroid hormone. J Endocrinol. 1980;85:161-170.
5. Abbott SR, Nissenson RA, Teitelbaum AP, Clark OH, Arnaud CD. Biologically active parathyroid hormone in human hyperparathyroid serum: assay and characterization. Trans Assoc Am Physicians. 1980;93:192-202.
6. Arnaud CD. Parathyroid hormone: coming of age in clinical medicine [editorial]. Am J Med. 1973;55:577-581.
7. Bauer W, Federman DD. Hyperparathyroidism epitomized: the case of Captain Charles E. Martell. Metabolism. 1962;11:21-29.
8. Diaz-Buxo JA, Knox FG. Effects of parathyroid hormone on renal function. Mayo Clin Proc. 1975;50:537-541.
9. Knox FG, Greger RF, Lang FC, Marchand GR. Renal handling of phosphate: update. Adv Exp Med Biol. 1977;81:3-14.
10. Broadus AE, Horst RL, Lang R, Littledike ET, Rasmussen H. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med. 1980;302:421-426.
11. Broadus AE, Horst RL, Littledike ET, Mahaffey JE, Rasmussen H. Primary hyperparathyroidism with intermittent hypercalcaemia: serial observations and simple diagnosis by means of an oral calcium tolerance test. Clin Endocrinol (Oxf). 1980;12:225-235.
12. Chase LR, Aurbach GD. Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin. Science. 1968;159:545-547.
13. Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: defective excretion of 3′,5′-AMP in response to parathyroid hormone. J Clin Invest. 1969;48:1832-1844.
14. Aurbach GD, Keutmann HT, Niall HD, et al. Structure, synthesis, and mechanism of action of parathyroid hormone. Recent Prog Horm Res. 1972;28:353-398.
15. Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore), 1974;53:127-146.
16. Knox FG, Schneider EG, Willis LR, Strandhoy JW, Ott CE. Site and control of phosphate reabsorption by the kidney [editorial]. Kidney Int. 1973;3:347-353.
17. Knox FG, Osswald H, Marchand GR, et al. Phosphate transport along the nephron. Am J Physiol. 1977;233:F261-F268.
18. Traebert M, Roth J, Biber J, Murer H, Kaissling B. Internalization of proximal tubular type II Na-P(i) cotransporter by PTH: immunogold electron microscopy. Am J Physiol Renal Physiol. 2000;278:F148-F154.
19. Pfister MF, Ruf I, Stange G, et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci U S A. 1998;95:1909-1914.
20. Keusch I, Traebert M, Lotscher M, Kaissling B, Murer H, Biber J. Parathyroid hormone and dietary phosphate provoke a lysosomal routing of the proximal tubular Na/Pi-cotransporter type II. Kidney Int. 1998;54:1224-1232.
21. Murayama A, Takeyama K, Kitanaka S, et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology. 1999;140:2224-2231.
22. Garabedian M, Holick MF, DeLuca HF, Boyle IT. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc Natl Acad Sci U S A. 1972;69:1673-1676.
23. DeLuca HF, Schnoes HK. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem. 1976;45:631-666.
24. DeLuca HF, Schnoes HK. Vitamin D: recent advances. Annu Rev Biochem. 1983;52:411-439.
25. Tanaka Y, DeLuca HF, Omdahl J, Holick MF. Mechanism of action of 1,25-dihydroxycholecalciferol on intestinal calcium transport. Proc Natl Acad Sci U S A. 1971;68:1286-1288.
26. Omdahl J, Holick M, Suda T, Tanaka Y, DeLuca HF. Biological activity of 1,25-dihydroxycholecalciferol. Biochemistry. 1971;10:2935-2940.
27. Tanaka Y, DeLuca HF. Role of 1,25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc Natl Acad Sci U S A. 1974;71:1040-1044.
28. Johnson JA, Kumar R. Renal and intestinal calcium transport: roles of vitamin D and vitamin D-dependent calcium binding proteins. Semin Nephrol. 1994;14:119-128.
29. Kaune R, Kassianoff I, Schroder B, Harmeyer J. The effects of 1,25-dihydroxyvitamin D-3 deficiency on Ca(2+)-transport and Ca(2+)-uptake into brush-border membrane vesicles from pig small intestine. Biochim Biophys Acta. 1992;1109:187-194.
30. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-1663.
31. Hoogendoom EH, White KE, Econs MJ, Hermus AR. Hypophosphatemia, osteomalacia and proximal muscle weakness treated by surgery [letter]. Clin Endocrinol (Oxf). 2003;58:796-797.
32. Nelson AE, Bligh RC, Mirams M, et al. Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088-4094.
33. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004;65:1-14.
34. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens. 2002;11:547-553.
35. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 2003;285:E1-E9.
36. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-2279.
37. Singh RJ, Kumar R. Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc. 2003;78:826-829.
38. Kelly TG, Mitnick M, Insogna KL, Carpenter TO. FGF23 in rickets and primary hyperparathyroidism: evidence for PTH regulation of circulating FGF23 levels [abstract]. Presented at: The Endocrine Society 85th Annual Meeting; Philadelphia, Pa; June 19-22, 2003.
39. Klee GG, Preissner CM, Schryver PG, Taylor RL, Kao PC. Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin. Clin Chem. 1992;38:628-635.
40. Tanaka Y, DeLuca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys. 1973;154:566-574.
41. Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003;278:9843-9849.
42. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278:2206-2211.
43. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001;284:977-981.
44. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone. 2000;27:333-338.
45. Kumar R. Phosphatonin - a newphosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia) [editorial]. Nephrol Dial Transplant. 1997;12:11-13.
46. Allen HC, Whybro A, Barker ME, Eastell R, Blumsohn A. Endocrine response to escalating-dose phosphate supplementation in men: is FGF-23 phosphatonin? [abstract]. J Bone Miner Res. 2002;17(suppl 1):S159. Abstract 1144.